Siemens' gets US nod for shock wave therapy:
This article was originally published in Clinica
The US FDA has approved Siemens Medical Solutions' SONOCUR basic, a low-energy extracorporeal shock wave therapy system for treating lateral epicondylitis, a condition commonly known as tennis elbow. The company's multicentre, 114-patient, US clinical trial showed that 64% of patients treated with the system achieved at least a 50% reduction in pain at a 12-week follow-up. The trial, said the company, demonstrated that treatment with the device can provide a noninvasive alternative to surgery for patients who have failed to respond to conventional therapies.
You may also be interested in...
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.